High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia-Reference-Cited by-同舟云学术

High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia

Published:2019-10-15 Issue:2 Volume:221 Page:218-222
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Chihota Belinda V¹²,Wandeler Gilles²³,Chilengi Roma¹,Mulenga Lloyd⁴⁵,Chung Raymond T⁶,Bhattacharya Debika⁷,Egger Mathias²⁸,Vinikoor Michael J¹⁴⁹

Affiliation:

1. Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

2. Institute of Social and Preventative Medicine, University of Bern, Bern, Switzerland

3. Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland

4. School of Medicine, University of Zambia, Lusaka, Zambia

5. Ministry of Health, Lusaka, Zambia

6. Liver Center and Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

7. Division of Infectious Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA

8. Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, South Africa

9. Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA

Abstract

Abstract Among 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia, median baseline CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive. Within 2 years of therapy, 29 (10.2%) participants experienced HBV functional cure (confirmed loss of hepatitis B surface antigen). In multivariable analysis, baseline CD4 count <350 cells/mm3, female sex, and lower baseline HBV deoxyribonucleic acid were associated with increased odds of functional cure. Immune recovery during HIV-HBV treatment with ART may drive higher rates of functional cure than during HBV monoinfection treatment. Understanding the mechanisms underlying this phenomenon could inform immunomodulatory therapies for HBV cure.

Funder

National Institute of Allergy and Infectious Diseases

Fogarty International Center

National Institutes of Health

Swiss National Science Foundation

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiz450/30153195/jiz450.pdf

Reference15 articles.